Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 5/20 | 0.67 |
| ▸ | MEN1 | O00255 | 2/20 | 0.67 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.59 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.59 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.59 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.59 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.59 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.59 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.59 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.59 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.57 |
| ▸ | GPR35 | Q9HC97 | 2/20 | 0.55 |
| ▸ | TP53 | P04637 | 1/20 | 0.55 |
| ▸ | HPGD | P15428 | 1/20 | 0.55 |
| ▸ | TSHR | P16473 | 1/20 | 0.55 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.55 |
| ▸ | TXNRD1 | Q16881 | 1/20 | 0.53 |
| ▸ | TXNRD3 | Q86VQ6 | 1/20 | 0.53 |
| ▸ | TXNRD2 | Q9NNW7 | 1/20 | 0.53 |
| ▸ | GUSB | P08236 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19419900 | 0.90 | MEN1 (0.57) | KMT2AMEN1ALDH1A1MAPK1HIF1A | |
| SCHEMBL3722506 | 0.86 | ALDH1A1 (0.58) | KMT2AMEN1ALDH1A1MAPK1HIF1A | |
| SCHEMBL11589518 | 0.85 | KMT2A (0.68) | KMT2AMEN1ALDH1A1MAPK1HIF1A | |
| SCHEMBL11856235 | 0.85 | KIF18A (0.68) | KMT2AMEN1ALDH1A1MAPK1HIF1A | |
| SCHEMBL17259 | 0.85 | ALDH1A1 (0.56) | KMT2AMEN1ALDH1A1MAPK1HIF1A | |
| SCHEMBL3148717 | 0.85 | ALDH1A1 (0.56) | KMT2AMEN1ALDH1A1MAPK1HIF1A | |
| SCHEMBL57260 | 0.85 | ALDH1A1 (0.56) | KMT2AMEN1ALDH1A1MAPK1HIF1A | |
| SCHEMBL63183 | 0.85 | KMT2A (0.59) | KMT2AMEN1ALDH1A1MAPK1HIF1A | |
| SCHEMBL31294358 | 0.85 | ALDH1A1 (0.56) | KMT2AMEN1ALDH1A1MAPK1HIF1A | |
| SCHEMBL1363964 | 0.85 | KMT2A (0.59) | KMT2AMEN1ALDH1A1MAPK1HIF1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170122954-A1 | PROFILING REACTIVE OXYGEN, NITROGEN AND HALOGEN SPECIES | ENZO LIFE SCIENCES, INC., C/O ENZO BIOCHEM, INC. (US) | 2017-05-04 | — | — | US | claimed |
| US-20150192564-A1 | PROFILING REACTIVE OXYGEN, NITROGEN AND HALOGEN SPECIES | ENZO LIFE SCIENCES, INC., C/O ENZO BIOCHEM, INC. (US) | 2015-07-09 | — | — | US | claimed |
| EP-2335052-A1 | PROFILING REACTIVE OXYGEN, NITROGEN AND HALOGEN SPECIES | Enzo Life Sciences, Inc. (US) | 2011-06-22 | — | — | EP | claimed |
| WO-2010036922-A1 | PROFILING REACTIVE OXYGEN, NITROGEN AND HALOGEN SPECIES | ENZO LIFE SCIENCES, INC. (US) | 2010-04-01 | — | — | WO | claimed |
| US-20100081159-A1 | Profiling reactive oxygen, nitrogen and halogen species | ENZO LIFE SCIENCES, INC. C/O ENZO BIOCHEM, INC. | 2010-04-01 | — | — | US | claimed |
| US-20170281649-A1 | COMPOUNDS AND THERAPEUTIC USES | UNITY BIOTECHNOLOGY, INC. | 2017-10-05 | — | — | US | disclosed |
| US-20170122954-A1 | PROFILING REACTIVE OXYGEN, NITROGEN AND HALOGEN SPECIES | ENZO LIFE SCIENCES, INC., C/O ENZO BIOCHEM, INC. (US) | 2017-05-04 | — | — | US | disclosed |
| US-20150192564-A1 | PROFILING REACTIVE OXYGEN, NITROGEN AND HALOGEN SPECIES | ENZO LIFE SCIENCES, INC., C/O ENZO BIOCHEM, INC. (US) | 2015-07-09 | — | — | US | disclosed |
| US-8865901-B2 | Gain-of-function Bcl-2 inhibitors | FRED HUTCHINSON CANCER RESEARCH CENTER (US) | 2014-10-21 | — | — | US | disclosed |
| US-8865901-B2 | Gain-of-function Bcl-2 inhibitors | FRED HUTCHINSON CANCER RESEARCH CENTER (US) | 2014-10-21 | — | — | US | disclosed |
| US-20120252839-A1 | GAIN-OF-FUNCTION BCL-2 INHIBITORS | FRED HUTCHINSON CANCER RESEARCH CENTER (US) | 2012-10-04 | — | — | US | disclosed |
| US-20120252839-A1 | GAIN-OF-FUNCTION BCL-2 INHIBITORS | FRED HUTCHINSON CANCER RESEARCH CENTER (US) | 2012-10-04 | — | — | US | disclosed |
| EP-2335052-A1 | PROFILING REACTIVE OXYGEN, NITROGEN AND HALOGEN SPECIES | Enzo Life Sciences, Inc. (US) | 2011-06-22 | — | — | EP | disclosed |
| WO-2011041731-A2 | METHOD OF INHIBITING BCL-2-RELATED SURVIVAL PROTEINS | FRED HUTCHINSON CANCER RESEARCH CENTER (US) | 2011-04-07 | — | — | WO | disclosed |
| WO-2010036922-A1 | PROFILING REACTIVE OXYGEN, NITROGEN AND HALOGEN SPECIES | ENZO LIFE SCIENCES, INC. (US) | 2010-04-01 | — | — | WO | disclosed |
| US-20100081159-A1 | Profiling reactive oxygen, nitrogen and halogen species | ENZO LIFE SCIENCES, INC. C/O ENZO BIOCHEM, INC. | 2010-04-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170281649-A1 | COMPOUNDS AND THERAPEUTIC USES | TP53, NQO1, SHMT2 | KMT2A 3471/4885MEN1 3416/4885ALDH1A1 545/4885 |
| US-20120252839-A1 | GAIN-OF-FUNCTION BCL-2 INHIBITORS | BCL2, BCL2L1, BCL2L2 | KMT2A 2897/4885MEN1 1948/4885ALDH1A1 4020/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.